Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is MEDIROM Healthcare Technologies EV-to-EBITDA?
MEDIROM Healthcare TechnologiesMRM -10.10%53 EV-to-EBITDA is 17.35 as of Aug. 03, 2026, which is 34% above its 10-year median of 12.94. GuruFocus rates MRM with a GF Score™ of 53/100 and a GF Value™ of $4.07 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 75 Personal Services companies, MEDIROM Healthcare Technologies ranks worse than 84% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, MEDIROM Healthcare Technologies's enterprise value is $35.64 Mil.
MEDIROM Healthcare Technologies's EBITDA for the trailing twelve months (TTM) ended in Jun. 2025 was $2.05 Mil. Therefore, MEDIROM Healthcare Technologies's EV-to-EBITDA for today is 17.35.
The historical rank and industry rank for MEDIROM Healthcare Technologies's EV-to-EBITDA or its related term are showing as below:
MRM'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -24.95 Med: 12.94 Max: 26.47
Current: 17.35
During the past 7 years, the highest EV-to-EBITDA of MEDIROM Healthcare Technologies was 26.47. The lowest was -24.95. And the median was 12.94.
MRM's EV-to-EBITDA is ranked worse than 84% of 75
companies
in the Personal Services industry
Industry Median: 7.44
vs MRM: 17.35
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
MEDIROM Healthcare Technologies's PE Ratio (TTM) for today is calculated as:
MEDIROM Healthcare Technologies's share price for today is $0.89.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. MEDIROM Healthcare Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 was $0.351.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Personal Services subindustry, MEDIROM Healthcare Technologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MEDIROM Healthcare Technologies EV-to-EBITDA vs Personal Services Industry
For the Personal Services industry and Consumer Cyclical sector, MEDIROM Healthcare Technologies's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where MEDIROM Healthcare Technologies's EV-to-EBITDA falls into.
MEDIROM Healthcare Technologies's current Enterprise Value is $35.64 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. MEDIROM Healthcare Technologies's EBITDA for the trailing twelve months (TTM) ended in Jun. 2025 was $2.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEDIROM Healthcare Technologies (MRM) has a EV-to-EBITDA of 17.35 as of Aug. 03, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on MEDIROM Healthcare Technologies. This is 34% above median its historical median of 12.94. According to the industry distribution chart, MEDIROM Healthcare Technologies ranks #63 out of 75 companies in the Personal Services industry, placing it in the top 84%.
Is MEDIROM Healthcare Technologies' EV-to-EBITDA too high?
MEDIROM Healthcare Technologies' current EV-to-EBITDA of 17.35 is 34% above median its 10-year median of 12.94. The Personal Services industry median EV-to-EBITDA is 7.44. MEDIROM Healthcare Technologies' value of 17.35 is 133.2% above this industry median. Based on the distribution chart, MEDIROM Healthcare Technologies ranks #63 out of 75 companies in the Personal Services industry, which is in the bottom quartile relative to peers. Overall, MEDIROM Healthcare Technologies has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MEDIROM Healthcare Technologies' EV-to-EBITDA compare to EJH and DROR?
According to the Personal Services industry distribution chart, MEDIROM Healthcare Technologies ranks #63 out of 75 companies for EV-to-EBITDA. This places MEDIROM Healthcare Technologies in the lower half of its industry. The industry median EV-to-EBITDA is 7.44. MEDIROM Healthcare Technologies' value of 17.35 is 133.2% above this benchmark. While the company's 10-year median is 12.94 vs. the industry median of 7.44, MEDIROM Healthcare Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Personal Services company?
The median EV-to-EBITDA among Personal Services companies is 7.44, based on 75 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MEDIROM Healthcare Technologies's current EV-to-EBITDA of 17.35 is 133.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on MEDIROM Healthcare Technologies. For the Personal Services industry, the median EV-to-EBITDA is 7.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MEDIROM Healthcare Technologies's current EV-to-EBITDA is 17.35, which is 34% above median its own 10-year median of 12.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MEDIROM Healthcare Technologies stock overvalued right now?
Based on GuruFocus' analysis, MEDIROM Healthcare Technologies (MRM) is currently considered Possible Value Trap. The stock's GF Value™ is $4.07, compared to a current price of $0.89 — trading 78.1% below its estimated fair value. The current EV-to-EBITDA is 17.35, which is 34% above median its 10-year median of 12.94 and 133.2% above the Personal Services industry median of 7.44. MEDIROM Healthcare Technologies' overall GF Score™ is 53/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For MEDIROM Healthcare Technologies (MRM), the current EV-to-EBITDA is 17.35 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MEDIROM Healthcare Technologies (MRM) Overvalued in 2026?
Based on GuruFocus' analysis, MEDIROM Healthcare Technologies stock appears to be undervalued.
The current stock price of $0.89 is trading 78.1% below its estimated GF Value™ of $4.07.
GuruFocus considers MEDIROM Healthcare Technologies to be Possible Value Trap.
Key valuation signals for MRM:
EV-to-EBITDA: 17.35 (34% above median its 10-year median of 12.94)
GF Value™: $4.07 vs. price of $0.89 (78.1% below fair value)
Industry Position: 133.2% above the Personal Services median (#63 of 75)
No single metric tells the full story. See the MRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
53GF Score
Get the complete analysis for MRM
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MRM has been successfully added to your 
